SCHEMBL299675

SCHEMBL299675

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCOC(=O)N3CCOCC3)c3ccccc23)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.80
TNF P01375 8/20 0.80
MAPK12 P53778 6/20 0.80
HCK P08631 3/20 0.80
MAPK13 O15264 2/20 0.80
MAPK11 Q15759 2/20 0.80
CIT O14578 1/20 0.80
MUSK O15146 1/20 0.80
MAP3K7 O43318 1/20 0.80
RIPK2 O43353 1/20 0.80
STK10 O94804 1/20 0.80
MAP4K4 O95819 1/20 0.80
CHEK2 O96017 1/20 0.80
ABL1 P00519 1/20 0.80
EGFR P00533 1/20 0.80
RAF1 P04049 1/20 0.80
NTRK1 P04629 1/20 0.80
HSPB1 P04792 1/20 0.80
PRKCB P05771 1/20 0.80
LCK P06239 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29594444 1.00 MAPK14 (0.80) MAPK14TNFMAPK12HCKMAPK13
Doramapimod SCHEMBL129721 0.89 MAPK14 (1.00) MAPK14TNFMAPK12HCKMAPK13
Doramapimod SCHEMBL29353023 0.89 MAPK14 (1.00) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL295388 0.89 MAPK14 (0.78) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL29594066 0.89 MAPK14 (0.78) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL20876996 0.88 MAPK14 (0.93) MAPK14TNFMAPK12HCKMAPK13
Doramapimod SCHEMBL10320344 0.88 MAPK14 (0.98) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL294689 0.86 MAPK14 (0.79) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL29594339 0.86 MAPK14 (0.79) MAPK14TNFMAPK12HCKMAPK13
SCHEMBL296487 0.84 MAPK14 (0.76) MAPK14TNFMAPK12HCKMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147104-B1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMA (US) 2012-03-14 EP claimed
CN-114748622-A P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD 弗尔康医疗公司 2022-07-15 CN disclosed
CN-114732910-A P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD 弗尔康医疗公司 2022-07-12 CN disclosed
CN-111601593-B P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD 弗尔康医疗公司 2022-04-15 CN disclosed
CN-111601593-A P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD 弗尔康医疗公司 2020-08-28 CN disclosed
EP-3691620-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019071147-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2019-04-11 WO disclosed
EP-1534282-A2 PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-06-01 EP disclosed
EP-1530477-A1 COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-05-18 EP disclosed
EP-1496900-A2 NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-01-19 EP disclosed
WO-2004014387-A1 COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-02-19 WO disclosed
WO-2004004725-A2 PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-15 WO disclosed
WO-2003084539-A2 NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND P38 KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-10-16 WO disclosed